Circulating Tumor Cells (CTC) in Cancer

March 10, 2025 updated by: University Hospital, Basel, Switzerland
This observational study with circulating tumor cells (CTC) count, isolation and analysis at several time points during disease progression is to investigate the role and biology of CTCs and clusters of CTCs in different cancer types. It also evaluates the role of CTCs as biomarkers, and aims at the identification of key signaling networks that are active in CTCs.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

3000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Switzerland
      • Basel, Switzerland, 4031
        • Recruiting
        • University Hospital Basel
        • Contact:
        • Principal Investigator:
          • Christian Kurzeder, PD Dr. med.
        • Sub-Investigator:
          • Fabienne Schwab, Dr. med
        • Sub-Investigator:
          • Viola Heinzelmann-Schwarz, Prof. Dr. med
        • Sub-Investigator:
          • Christoph Rochlitz, Prof. Dr. med.
        • Sub-Investigator:
          • Julia Landin, Dr. med.
        • Sub-Investigator:
          • Alfred Zippelius, Prof. Dr. med.
        • Sub-Investigator:
          • Heinz Läubli, PD Dr. med.
        • Sub-Investigator:
          • Walter Weber, Prof. Dr. med.
        • Sub-Investigator:
          • Dörthe Schaefer-Rohr, Dr. med.
        • Sub-Investigator:
          • Homen Begovic, Dr. med.
        • Sub-Investigator:
          • Christine Wenk, Dr. med.
        • Sub-Investigator:
          • Daniel Steffens, Dr. med.
        • Sub-Investigator:
          • Anna Schollbach, Dr. med.
        • Sub-Investigator:
          • Ilker Acemoglu, Dr. med.
        • Sub-Investigator:
          • Simone Münst, PD Dr. med.
        • Sub-Investigator:
          • Tatjana Vlajnic, Dr. med.
      • Liestal, Switzerland, 4410
        • Recruiting
        • Department Oncology, Haematology & Immuntherapy, Kantonsspital Baselland
        • Contact:
        • Sub-Investigator:
          • Robert Rosenberg, Prof. Dr. med.
        • Sub-Investigator:
          • Emanuel Burri, PD Dr. med.
        • Principal Investigator:
          • Marcus Vetter, PD Dr. med.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

adult patients (> 18 years) with a cancer diagnosis

Description

Inclusion Criteria:

  • Adult cancer patients
  • All patients with histology-based proved diagnosis of cancer, all stages and subtypes can be included. Precancerous lesions cannot be included.
  • All patients with the diagnosis of a solid tumor including adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, sarcoma
  • Written pathology report must be available.
  • Written informed consent.

Exclusion Criteria:

  • No written informed consent.
  • No proved diagnosis of malignancy by pathology report.
  • Patients with the diagnosis of blood cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival (OS) in heterogeneous cancer population
Time Frame: Screening (Visit 1) until the date of death (assessed up to 240 months)
overall survival (OS) in heterogeneous cancer population
Screening (Visit 1) until the date of death (assessed up to 240 months)
Change in total number of isolated CTCs
Time Frame: Through study completion, an average of 20 years
Change in total number of isolated CTCs
Through study completion, an average of 20 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression free survival (PFS)
Time Frame: Through study completion, an average of 20 years
progression free survival (PFS) in the different cancer cohorts with different treatment regimes
Through study completion, an average of 20 years

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in circulating tumor DNA (ctDNA) from blood samples
Time Frame: Through study completion, an average of 20 years
Change in circulating tumor DNA (ctDNA) from blood samples
Through study completion, an average of 20 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Basel, Switzerland

Investigators

  • Principal Investigator: Marcus Vetter, PD Dr. med., Kantonsspital Baselland, Liestal

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2020

Primary Completion (Estimated)

August 1, 2030

Study Completion (Estimated)

August 1, 2030

Study Registration Dates

First Submitted

August 5, 2020

First Submitted That Met QC Criteria

August 17, 2020

First Posted (Actual)

August 20, 2020

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 10, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2020-00014; me19Vetter

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on Blood samples

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe